May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Antimicrobial Efficacy of Gatifloxacin With and Without Benzalkonium Chloride Compared With Moxifloxacin Against Common Ocular Pathogens
Author Affiliations & Notes
  • S.D. Borsos
    Clinical Microbiology, Royal University Hospital, Saskatoon, SK, Canada
  • J.M. Blondeau
    Clinical Microbiology, Royal University Hospital, Saskatoon, SK, Canada
  • Footnotes
    Commercial Relationships  S.D. Borsos, None; J.M. Blondeau, Allergan, F; Allergan, R.
  • Footnotes
    Support  Allergan
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1892. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.D. Borsos, J.M. Blondeau; Antimicrobial Efficacy of Gatifloxacin With and Without Benzalkonium Chloride Compared With Moxifloxacin Against Common Ocular Pathogens . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1892.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the antimicrobial efficacy of gatifloxacin with and without benzalkonium chloride (BAK) compared with moxifloxacin against Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa.

Methods: : MIC testing was by microbroth dilution in accordance with the recommended CLSI procedure. Approximately 105 CFU/mL of each organism was added to appropriate media containing two–fold concentration increments of drug. For experiments containing BAK, 2.5 µL of a 10% solution was added to the first well of the plate to give a final BAK concentration of .0125%, and then was serially diluted with the drug; subsequently diluted at 1:2 when adding organisms to each well. Plates were incubated for 18 hours in ambient air and the lowest concentration showing no growth was recorded as the MIC.

Results: : The MIC90 values of gatifloxacin plus BAK were lower than the MIC90 values of either fluoroquinolone alone for every tested organism. Against specific organisms, the MIC90 values were as follows: H. influenzae: 0.004 µg/mL with gatifloxacin/BAK, 0.031 µg/mL with gatifloxacin, and 0.031 µg/mL with moxifloxacin; S. pneumoniae: 0.001 µg/mL with gatifloxacin/BAK, 0.25 µg/mL with gatifloxacin, and 0.125 µg/mL with moxifloxacin; S. aureus: 0.004 µg/mL with gatifloxacin/BAK, 0.063 µg/mL with gatifloxacin, and 0.031 µg/mL with moxifloxacin; P. aeruginosa: 0.5 µg/ml with gatifloxacin/BAK, 4.0 µg/mL with gatifloxacin, and 8.0 µg/mL with moxifloxacin.

Conclusions: : The combination of gatifloxacin and BAK was highly efficacious against a variety of common ocular pathogens in vitro, providing MIC90 values that were 8– to 125–fold lower than the moxifloxacin MIC90.

Keywords: antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×